BAMLANIVIMAB
BAMLANIVIMAB
Discontinued
DIN Number
02508176
Drug Class
Human
Market Date
Dec 24, 2020
Company
HC
eli lilly canada inc
Product Information
Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.
Product Details
Health Canada regulatory and product classification information
Regulatory Identifiers
DIN Number02508176
AIG Number0162600002
Classification & Schedule
C
Drug Class
Human
S
Schedule
COVID-19 - IO - Authorization
,
Schedule D
,
Prescription
A
ATC Code
J06B IMMUNOGLOBULINS
Product Specifications
Dosage FormSolution
Route of AdministrationIntravenous
AHFS Classification08:18.24
Health Canada Classification
ACTIVE INGREDIENTS (1)
BAMLANIVIMABActive
Strength: 700 MG / 20 ML
Monograph: BAMLANIVIMAB